

**NHS DORSET CLINICAL COMMISSIONING GROUP
PRIMARY CARE COMMISSIONING COMMITTEE
STOMA PRODUCT PRESCRIBING REPORT**

Date of the meeting	05/04/2017
Author	K Gough, Chief Pharmacist
Purpose of Report	The purpose of this report is to update the Committee on work that has successfully been undertaken on stoma ancillary products and seek a postponement of a planned piece of work on alternative methods of prescribing stoma products.
Recommendation	The Committee is asked to approve postponement of a business case to seek alternative means of prescribing/supplying stoma products.
Stakeholder Engagement	There are patient representatives on the Medicines Optimisation Group (MOG) and the GP prescribing leads for each locality are members of the MOG and work closely with the medicines team on prescribing issues
Previous GB / Committee/s, Dates	N/A

Monitoring and Assurance Summary

This report links to the following Strategic Principles	<ul style="list-style-type: none"> • Services designed around people • Preventing ill health and reducing inequalities • Sustainable healthcare services • Care closer to home 		
	Yes [e.g. ✓]	Any action required?	
		Yes Detail in report	No
All three Domains of Quality (Safety, Quality, Patient Experience)	✓		✓
Board Assurance Framework Risk Register	✓		✓
Budgetary Impact	✓		✓
Legal/Regulatory	✓		✓
People/Staff	✓		✓
Financial/Value for Money/Sustainability	✓		✓
Information Management & Technology	✓		✓
Equality Impact Assessment	✓		✓
Freedom of Information	✓		✓
I confirm that I have considered the implications of this report on each of the matters above, as indicated	✓		

Initials : KMG

1. Introduction

- 1.1 The purpose of this report is to update the committee on work that has successfully been undertaken on stoma ancillary products and seek a postponement of a planned piece of work on alternative methods of prescribing stoma products.

2. Report

- 2.1 In September 2016 an options appraisal was brought to this Committee meeting to consider how to take forward potential service changes to how stoma products are prescribed and managed in primary care.
- 2.2 The Primary Care Commissioning Committee (PCCC) instructed that this should return as a full business case only when a full equality impact assessment had been undertaken.
- 2.3 Due to various challenges with workload of the medicines team this has not yet been completed. The team has been focussed primarily on initiatives and guidance documents to support prescribing savings to meet the financial challenges. The stoma initiative is anticipated to be either cost neutral or have a small cost increase, but would involve a considerable workload.
- 2.4 Work that has been undertaken includes the development of a formulary for ancillary products for stoma patients, which is to be taken to the Dorset Medicines Advisory Group (DMAG) on 21 March. This is included in savings plans for 2017/18 and is hoped to save up to £70k through rationalisation of use of products and improved guidance on quantities, and this is planned to be implemented through 2017/18. The results of implementing this will be reviewed, and tracked.
- 2.5 In order to develop this formulary the stoma nurses across Dorset, as well as a patient representative, have been brought together to discuss the challenges and opportunities of rationalising the formulary with the medicines team.
- 2.6 It was proposed at the Medicines Optimisation Group (MOG) that the piece of work to review the Stoma prescribing systems is postponed so that the limited resources of the medicines team can be focussed on delivering prescribing savings to achieve the future financial challenges. The PCCC members are asked to support that postponement.
- 2.7 The medicines team is currently refocussing work on the need to utilise current staffing resources to provide pharmaceutical support to the programmes focussed on Right Care, primary care prescribing savings and efficiencies such as electronic prescriptions services and repeat dispensing services, maintaining and updating the formulary and statutory roles.
- 2.8 It is hoped that the outcomes of other CCG pilots on urology products and stoma products will be published in 2017/18 and will inform whether to proceed with this proposal in 2018/19.

3. Conclusion

- 3.1 The Committee is asked to **approve** the postponement of this piece of work for one year, with an update to be presented to this group in early 2018.

Author's name and Title : Katherine Gough, Chief Pharmacist

Date : March 2017

Telephone Number : 01305 368031